Yuejuan Cheng

Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study

Jianming Xu, Lin Shen, Chunmei Bai et al. · The Lancet Oncology · 2020 · 179 citations

Pancreatic Cancer, Medicine, Pathology +5

Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog ¹⁷⁷Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors

Jingjing Zhang, Hao Wang, Orit Jacobson et al. · Journal of Nuclear Medicine · 2018 · 93 citations · Full text

Head-to-Head Comparison of ⁶⁸Ga-DOTA-JR11 and ⁶⁸Ga-DOTATATE PET/CT in Patients with Metastatic, Well-Differentiated Neuroendocrine Tumors: A Prospective Study

Wenjia Zhu, Yuejuan Cheng, Xuezhu Wang et al. · Journal of Nuclear Medicine · 2019 · 79 citations · Full text

Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: A Multicenter, Single-Arm, Open-Label, Phase Ib/II Trial

Jian-Ming Xu, Jie Li, Chunmei Bai et al. · Clinical Cancer Research · 2019 · 76 citations

Unresectable pancreatic ductal adenocarcinoma: Role of CT quantitative imaging biomarkers for predicting outcomes of patients treated with chemotherapy

Sihang Cheng, Yuejuan Cheng, Zhengyu Jin et al. · European Journal of Radiology · 2019 · 52 citations

Pancreatic Cancer, Oncologic Imaging, Medical Imaging +6